Distinct Evolutionary Dynamics of HER2-Ultralow Versus HER2-Null from Residual to Metastatic Disease in Non-pCR Breast Cancer

Cancer Research and Treatment · Published 2026-05-12 · DOI 10.4143/crt.2026.0302

Free full text

Authors (7)

Shunan Wang, Jingjing Liu, Tong Liu, Shichao Zhang, Xinyu Liu, Yu Liu, Jin Zhang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Wang, S., Liu, J., Liu, T., et al. (2026). Distinct Evolutionary Dynamics of HER2-Ultralow Versus HER2-Null from Residual to Metastatic Disease in Non-pCR Breast Cancer. Cancer Research and Treatment. https://doi.org/10.4143/crt.2026.0302

Related articles

• Tumor-Intrinsic Hepatocyte Arm-Level Genomic States Shape Immunotherapy Response Heterogeneity in Hepatocellular Carcinoma · Cancer Research and Treatment · 2026 · Same journal
• Therapeutic Potential of Engineered Stem Cell Line with Chemokine Receptors and TRAIL/CD::UPRT in Glioblastoma Treatment · Cancer Research and Treatment · 2026 · Same journal
• Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023 · Cancer Research and Treatment · 2026 · Same journal
• A Prospective Study of Non‑Treating Medical Institution Use for Supportive Care During Adjuvant Chemotherapy After Curative Surgery (PRO-SUCCESS) · Cancer Research and Treatment · 2026 · Same journal
• A Phase I/II Trial to Evaluate the Safety and Efficacy of Continuous Positive Airway Pressure in Volumetric Modulated Arc Therapy for Breast Cancer · Cancer Research and Treatment · 2026 · Same journal
• Individual SGLT-2 Inhibitors and Risk of New-Onset Cancer in Type 2 Diabetes: A Nationwide Population-Based Cohort Study · Cancer Research and Treatment · 2026 · Same journal
• Integrative Genomic Analysis Reveals Molecular and Clinical Disparities between Bladder and Upper Tract Urothelial Carcinoma in K-MASTER Program · Cancer Research and Treatment · 2026 · Same journal
• Biomarker Testing Practices for Non-small Cell Lung Cancer: Survey Insights from South Korean Pathology Laboratories · Cancer Research and Treatment · 2026 · Same journal
• A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations · Cancer Research and Treatment · 2026 · Same journal
• Perceptions and Use of Complementary and Alternative Medicine among Patients with Cancer and Their Family Members (KCSG PC21-19) · Cancer Research and Treatment · 2026 · Same journal